---
title: The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia
nct_id: NCT03683810
overall_status: UNKNOWN
phase: PHASE1
sponsor: Cyprus University of Technology
study_type: INTERVENTIONAL
primary_condition: Anemia
countries: Cyprus
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03683810.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03683810"
ct_last_update_post_date: 2022-09-06
last_seen_at: "2026-05-12T06:54:23.313Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia

**Official Title:** The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia in Hematological Patients

**NCT ID:** [NCT03683810](https://clinicaltrials.gov/study/NCT03683810)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Cyprus University of Technology
- **Collaborators:** Hematological Clinic - Nicosia General Hospital, German Oncology Center, Cyprus, Limassol Hematology-oncology Center
- **Conditions:** Anemia
- **Start Date:** 2019-01-14
- **Completion Date:** 2023-06
- **CT.gov Last Update:** 2022-09-06

## Brief Summary

This will be a randomised control trial designed to test the effectiveness of lactoferrin in the management of treatment-induced anemia in patients with hematological malignancies.

## Detailed Description

Chemotherapy induced anemia (CIA) is a common adverse event in cancer patients reported to occur in 20-60% whilst the resulting low hemoglobin level is associated with impaired quality of life. Lactoferrin (LF) is a non-haem iron-binding protein that is part of the transferrin protein family, along with serum transferrin, ovotransferrin, melanotransferrin and the inhibitor of carbonic anhydrase, whose function is to transport iron in blood serum.

The aim of the study is to test the effectiveness of LF along with standard care in the management of treatment-induced anemia.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients on active treatment (chemotherapy i.e. cyclophosphamide, doxorubicin, rituximab, cisplatin carboplatin, etoposide)
* Ability to independently complete the questionnaires

Exclusion Criteria:

* Allergy to Milk
* Lactose intolerance
* Celiac disease
* Patient of whom chemotherapy has been interrupted for more than 2 weeks (due to adverse effects)
```

## Arms

- **Lactoferrin** (EXPERIMENTAL) — Participants will receive 4gr lactoferrin per day for a duration of 3 months + standard treatment for anemia
- **Standard treatment** (ACTIVE_COMPARATOR) — Participants will receive only the standard treatment for anemia

## Interventions

- **Lactoferrin** (DIETARY_SUPPLEMENT) — Lactoferrin in tablets 4g/daily
- **Recombinant human erythropoietin** (DRUG) — Recombinant human erythropoietin (rHuEPO, epoetin alfa)

## Primary Outcomes

- **Hemoglobin** _(time frame: Change from baseline at 2, 4, 6, 8, 10, 12)_ — Concentration of Hemoglobin levels in Serum

## Secondary Outcomes

- **Ferritin** _(time frame: Change from baseline at 2, 4, 6, 8, 10, 12)_
- **Cytokine** _(time frame: Change from baseline at 2, 4, 6, 8, 10, 12 weeks)_
- **LgG** _(time frame: Change from baseline at 2, 4, 6, 8, 10, 12 weeks)_
- **LgA** _(time frame: Change from baseline at 2, 4, 6, 8, 10, 12 weeks)_
- **LgM** _(time frame: Change from baseline at 2, 4, 6, 8, 10, 12 weeks)_
- **General Quality of LIfe** _(time frame: Change from baseline at 4, 8, 12 weeks)_
- **Health related quality of life** _(time frame: Change from baseline at 4, 8, 12 weeks)_
- **Functional Assessment of Cancer Therapy Anemia** _(time frame: Change from baseline at 4, 8, 12 weeks)_

## Locations (2)

- Hematology-Oncology Center, Limassol, Cyprus — _RECRUITING_
- Nicosia General Hospital, Nicosia, Cyprus — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hematology-oncology center|limassol||cyprus` — added _(2026-05-12)_
- `locations.nicosia general hospital|nicosia||cyprus` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03683810.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03683810*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*